Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats motor fluctuations. Sold as Vyalev. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Foscarbidopa; Foslevodopa (sold as Vyalev), first approved Oct 16, 2024, with 0 new uses approved and 2 published complete response letters.
First approved: Oct 16, 2024
Applications: 1
New uses approved: 0
Complete response letters: 2
Medicare spending, 2025: $8.9M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Vyalev
Part D
$8.9M
New
247
FDA Drug Safety Communications
One communication since 2020 that name this drug; see all communications
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Abbvie